Patents by Inventor Juan José Marugán
Juan José Marugán has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230056497Abstract: Compounds of Formula I, Formula II, and Formula III and the pharmaceutically acceptable salts thereof are disclosed. The variables X, a, b, c, d, R1-4, R10-15 and R17-22 are disclosed herein. The compounds are useful for treating cancer disorders, especially those involving M2 phenotype of macrophages. Pharmaceutical compositions containing compounds of Formula I or Formula II or Formula III and methods of treatment comprising administering compounds of Formula I and Formula II and Formula III are also disclosed.Type: ApplicationFiled: December 16, 2020Publication date: February 23, 2023Inventors: Raul Rolando Calvo, Bolormaa Baljinnyam, Andres Eduardo Dulcey, Udo Rudloff, Mark James Henderson, Juan Jose Marugan, Xin Hu, Noel Terrence Southall, Rushikesh Vilas Sable
-
Patent number: 11471460Abstract: Disclosed is method for treating cancer in a mammal, comprising administering to a mammal in need thereof a compound of the formula: wherein R1, R2, and R3 are as defined herein, wherein the cancer is an autophagy-dependent cancer, in an amount sufficient to induce autophagy in the cell and cause the death of cancer cells. Also disclosed is a method for selectively killing cancer cells in a patient afflicted with cancer, comprising administering to the mammal, wherein the cancer cells are autophagy-dependent cancer cells, in an amount sufficient to induce autophagy in the cells and cause the death of the cancer cells.Type: GrantFiled: May 26, 2020Date of Patent: October 18, 2022Assignee: The United States of Americans represented by the Secretary, Department of Health and Human ServicesInventors: Melvin L. DePamphilis, Gaurav Sharma, Juan Jose Marugan, Marc Ferrer, Ajit Roy
-
Publication number: 20220315548Abstract: This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having a phenyl-sulfonic amide (or similar) structure which function as agonists of mucolipin 1 (ML1), and their use as therapeutics for the treatment of Duchenne muscular dystrophy (DMD) and related disorders.Type: ApplicationFiled: August 28, 2020Publication date: October 6, 2022Inventors: Haoxing Xu, Lu Yu, Juan Jose Marugan, Raul Rolando Calvo, Natalia Julia Martinez, Noel Terrence Southall, Marc Ferrer, Xin Hu
-
Patent number: 11241436Abstract: The invention provides a compound of formula (I): wherein R1, R2, R3, and R4 are as defined herein, ginsenoside Rg2 of structure (II): or a combination thereof, for use in treating or preventing a condition responsive to the induction of autophagy in a brain of a mammal in need thereof.Type: GrantFiled: January 25, 2018Date of Patent: February 8, 2022Assignees: Northwestern University, The United States of Americans represented by the Secretary, Department of Health and Human Services, University of KansasInventors: Congcong He, Sui Huang, Chen Wang, Altea Rocchi, Juan Jose Marugan, Marc Ferrer, Samarjit Patnaik, Yuchi Chen, Kevin Frankowski, Frank J. Schoenen
-
Publication number: 20210186972Abstract: Disclosed are pharmaceutical formulations comprising a compound of formula (I): in which R1, R2, R3, and R4 are as described herein, or a pharmaceutically acceptable salt thereof. Also provided are methods for treating pancreatic adenocarcinoma comprising administration of a compound of formula (I), or a pharmaceutically acceptable salt thereof, and methods of detecting the change in expression levels of one or both of FoxA1 and FoxO6 in a pancreatic adenocarcinoma tumor sample from a mammal, wherein the mammal has been administered a compound of formula (I), or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: May 15, 2019Publication date: June 24, 2021Applicants: The United States of America,as represented by the Secretary,Department of Health and Human Services, University of Kansas, Northwestern UniversityInventors: Udo Rudloff, Serguei Kozlov, Juan Jose Marugan, Sui Huang, Samarjit Patnaik, John C. Braisted, Noel T. Southall, Marc Ferrer, Christopher Dextras, John Haslam, Michael Baltezor
-
Patent number: 10925874Abstract: Substituted pyrazolopyrimidines and dihydropyrazolopyrimidines and related compounds, their methods of manufacture, compositions containing these compounds, and methods of use of these compounds in treating lysosomal storage disorders such as Gaucher disease are described herein. The compounds are of general Formula (I) in which variables R1-R7 and X are described in the application.Type: GrantFiled: May 18, 2018Date of Patent: February 23, 2021Assignee: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICESInventors: Juan Jose Marugan, Noel Southall, Ehud Goldin, Wei Zheng, Samarjit Patnaik, Ellen Sidransky, Omid Motabar, Wendy Westbroek
-
Publication number: 20200369649Abstract: Disclosed is method for treating cancer in a mammal, comprising administering to a mammal in need thereof a compound of the formula: wherein R1, R2, and R3 are as defined herein, wherein the cancer is an autophagy-dependent cancer, in an amount sufficient to induce autophagy in the cell and cause the death of cancer cells. Also disclosed is a method for selectively killing cancer cells in a patient afflicted with cancer, comprising administering to the mammal, wherein the cancer cells are autophagy-dependent cancer cells, in an amount sufficient to induce autophagy in the cells and cause the death of the cancer cells.Type: ApplicationFiled: May 26, 2020Publication date: November 26, 2020Applicant: The United States of America,as represented by the Secretary,Department of Health and Human ServicesInventors: Melvin L. DePamphilis, Gaurav Sharma, Juan Jose Marugan, Marc Ferrer, Ajit Roy
-
Publication number: 20200009146Abstract: The invention provides a compound of formula (I): wherein R1, R2, R3, and R4 are as defined herein, ginsenoside Rg2 of structure (II): or a combination thereof, for use in treating or preventing a condition responsive to the induction of autophagy in a brain of a mammal in need thereof.Type: ApplicationFiled: January 25, 2018Publication date: January 9, 2020Applicants: Northwestern University, The United States of America, as Represented by the Secretary, Department of Health & Human Services, University of KansasInventors: Congcong HE, Sui HUANG, Chen WANG, Altea ROCCHI, Juan Jose MARUGAN, Marc FERRER, Samarjit PATNAIK, Yuchi CHEN, Kevin FRANKOWSKI, Frank J. SCHOENEN
-
Patent number: 10370348Abstract: The subject invention relates to improved tocopheryl quinine derivatives and tocopherol derivatives having improved pharmacokinetics in vivo that can, in some embodiments, be useful in the treatment of Lysosomal Storage Disorder, restoration of normal mitochondrial ATP production, modulation of intracellular calcium ion concentration and other treatments or therapies. The tocopheryl quinone derivatives and tocopherol derivatives have side chains that have terminally halogenated carbon atoms.Type: GrantFiled: May 30, 2017Date of Patent: August 6, 2019Assignee: The United States of America, as Represented by the Secretary, Department of Health and Human ServicesInventors: Juan Jose Marugan, Wei Zheng, Jingbo Xiao, John McKew
-
Patent number: 10301314Abstract: The disclosure provides compounds for reducing the prevalence of the perinucleolar compartment in cells, for example, of formula (I), wherein R1, R2, R3, and R4 are as defined herein, that are useful in treating a disease or disorder associated with increased prevalence of the perinucleolar compartment, such as cancer. Also disclosed is a composition containing a pharmaceutically acceptable carrier and at least one compound embodying the principles of the invention, and a method of treating or preventing cancer in a mammal.Type: GrantFiled: May 26, 2017Date of Patent: May 28, 2019Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, University of Kansas, Northwestern UniversityInventors: Kevin Frankowski, Samarjit Patnaik, Sui Huang, Juan Jose Marugan, John Norton, Frank J. Schoenen, Noel Terrence Southall, Steven Titus, Wei Zheng, Chen Wang
-
Patent number: 10239830Abstract: Methods and compositions for treating lysosomal storage disorders are disclosed. The methods involve administering a genus of benzenesulfonamides, particularly N-[3-(aminosulfonyl)phenyl]-benzamides and heteroarylamides.Type: GrantFiled: February 11, 2016Date of Patent: March 26, 2019Assignees: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, The United States of America, as represented by the Secretary, Depart. of Health and Human ServicesInventors: Samarjit Patnaik, Mercedes Taylor, Raul Rolando Calvo, Juan Jose Marugan, Noel Southall, Wei Zheng, Marc Ferrer-Alegre, Seameen Dehdasthi, Patricia Dranchak, Fannie Chen, Yiannis Ioannou
-
Patent number: 10202367Abstract: Disclosed are compounds of formula (I), formula (II), and formula (III): wherein Ar, R1, A, and X are as defined in the specification. These compounds are antiviral agents and are contemplated for use in the treatment of viral infections, for example, hepatitis C. These compounds are also contemplated for use in treating or preventing cancers.Type: GrantFiled: June 12, 2015Date of Patent: February 12, 2019Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, University of KansasInventors: Tsanyang Liang, Zongyi Hu, Juan Jose Marugan, Noel Terrence Southall, Shanshan He, Xin Hu, Jingbo Xiao, Marc Ferrer, Wei Zheng, Kevin J. Frankowski, Frank J. Schoenen, Kelin Li
-
Patent number: 10125112Abstract: Disclosed are modulators of the human relaxin receptor 1, for example, of formula (I), wherein A, R1, and R2 are as defined herein, that are useful in treating mammalian relaxin receptor 1 mediated facets of human health, e.g., cardiovascular disease. Also disclosed is a composition comprising a pharmaceutically suitable carrier and at least one compound of the disclosure, and a method for therapeutic intervention in a facet of mammalian health that is mediated by a human relaxin receptor 1.Type: GrantFiled: August 25, 2016Date of Patent: November 13, 2018Assignees: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEESInventors: Juan Jose Marugan, Jingbo Xiao, Marc Ferrer-Alegre, Catherine Chen, Noel Southall, Wei Zheng, Alexander Agoulnik, Irina Agoulnik
-
Publication number: 20180263988Abstract: Substituted pyrazolopyrimidines and dihydropyrazolopyrimidines and related compounds, their methods of manufacture, compositions containing these compounds, and methods of use of these compounds in treating lysosomal storage disorders such as Gaucher disease are described herein. The compounds are of general Formula (I) in which variables R1-R7 and X are described in the application.Type: ApplicationFiled: May 18, 2018Publication date: September 20, 2018Inventors: Juan Jose Marugan, Noel Southall, Ehud Goldin, Wei Zheng, Samarjit Patnaik, Ellen Sidransky, Omid Motabar, Wendy Westbroek
-
Patent number: 10039741Abstract: This disclosure relates generally to the treatment of lysosomal storage disorders. Specifically, the disclosure relates to a novel use of ? tocopherol in the treatment of diseases and conditions related to lysosomal storage disorders. Included in the present disclosure is a method for the modulation of cholesterol recycling. Further, the disclosure relates to conditions such as Niemann-Pick type C disease, Farber disease, Niemann-Pick type A disease, Wolman disease and Tay Sachs disease. Further included in the present disclosure is a method for treating lysosomal storage disorders comprising the administration of ? tocopherol. Further included in the present disclosure is a method for treating lysosomal storage disorders comprising the administration of ? tocopherol in combination with cyclodextrin to a patient in need thereof.Type: GrantFiled: August 17, 2016Date of Patent: August 7, 2018Assignee: The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Wei Zheng, Juan Jose Marugan, Ke Liu, Noel Terrence Southall, Christopher P. Austin
-
Patent number: 9974789Abstract: Substituted pyrazolopyrimidines and dihydropyrazolopyrimidines and related compounds, their methods of manufacture, compositions containing these compounds, and methods of use of these compounds in treating lysosomal storage disorders such as Gaucher disease are described herein. The compounds are of general Formula (I) in which variables R1-R7 and X are described in the application.Type: GrantFiled: April 28, 2016Date of Patent: May 22, 2018Assignee: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICESInventors: Juan Jose Marugan, Noel Southall, Ehud Goldin, Wei Zheng, Samarjit Patnaik, Ellen Sidransky, Omid Motabar, Wendy Westbroek
-
Publication number: 20180105506Abstract: The subject invention relates to improved tocopheryl quinine derivatives and tocopherol derivatives having improved pharmacokinetics in vivo that can, in some embodiments, be useful in the treatment of Lysosomal Storage Disorder, restoration of normal mitochondrial ATP production, modulation of intracellular calcium ion concentration and other treatments or therapies. The tocopheryl quinone derivatives and tocopherol derivatives have side chains that have terminally halogenated carbon atoms.Type: ApplicationFiled: May 30, 2017Publication date: April 19, 2018Inventors: Juan Jose MARUGAN, Wei ZHENG, Jingbo XIAO, John MCKEW
-
Publication number: 20180044286Abstract: Methods and compositions for treating lysosomal storage disorders are disclosed. The methods involve administering a genus of benzenesulfonamides, particularly N-[3-(aminosulfonyl)phenyl]-benzamides and heteroarylamides.Type: ApplicationFiled: February 11, 2016Publication date: February 15, 2018Applicants: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, and Human ServicesInventors: Samarjit PATNAIK, Mercedes TAYLOR, Raul Rolando CALVO, Juan Jose MARUGAN, Noel SOUTHALL, Wei ZHENG, Marc FERRER-ALEGRE, Seameen DEHDASTHI, Patricia DRANCHAK, Fannie CHEN, Yiannis IOANNOU
-
Publication number: 20170260192Abstract: The disclosure provides compounds for reducing the prevalence of the perinucleolar compartment in cells, for example, of formula (I), wherein R1, R2, R3, and R4 are as defined herein, that are useful in treating a disease or disorder associated with increased prevalence of the perinucleolar compartment, such as cancer. Also disclosed is a composition containing a pharmaceutically acceptable carrier and at least one compound embodying the principles of the invention, and a method of treating or preventing cancer in a mammal.Type: ApplicationFiled: May 26, 2017Publication date: September 14, 2017Applicants: The United States of America, as represented by the Secretary, Dept of Health and Human Services, University of Kansas, Northwestern UniversityInventors: Kevin Frankowski, Samarjit Patnaik, Sui Huang, Juan Jose Marugan, John Norton, Frank J. Schoenen, Noel Terrence Southall, Steven Titus, Wei Zheng
-
Patent number: 9663521Abstract: The disclosure provides compounds for reducing the prevalence of the perinucleolar compartment in cells, for example, of formula (I), wherein R1, R2, R3, and R4 are as defined herein, that are useful in treating a disease or disorder associated with increased prevalence of the perinucleolar compartment, such as cancer. Also disclosed is a composition containing a pharmaceutically acceptable carrier and at least one compound embodying the principles of the invention, and a method of treating or preventing cancer in a mammal.Type: GrantFiled: December 17, 2012Date of Patent: May 30, 2017Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, University of Kansas, Northwestern UniversityInventors: Kevin Frankowski, Samarjit Patnaik, Sui Huang, Juan Jose Marugan, John Norton, Frank J. Schoenen, Noel Terrence Southall, Steven Titus, Wei Zheng